Magdalena Harris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Magdalena Harris has a total of 320 co-authors. Here are the top co-authors by number of shared publications:
- Dan Lewer
Bradford Health Data Science Bradford England BD96RJ Bradford Institute for Health Research
14 shared publications - Tim Rhodes
London School of Hygiene and Tropical Medicine London UK
13 shared publications - Jenny Scott
Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, United Kingdom
12 shared publications - Adam Holland
University of Bristol
10 shared publications - Vivian D. Hope
Public Health Institute and School of Public and Allied Health, Liverpool John Moores University, 3rd Floor Tithebarn Building, 79 Tithebarn Street, Liverpool, L2 2ER, United Kingdom
8 shared publications Vivian Hope
Public Health Institute / School of Public and Allied Health, Liverpool John Moores University, Liverpool, UK
8 shared publications
Latest Publications
- Open Access
- 7 July 2026
- Published by BMJ in BMJ Open Quality
- Vol. 15 (3) , e004153
Improving opioid substitution therapy in the acute hospital setting: implementation of a best practice guideline
Background: Delayed provision of opioid substitution therapy (OST) in acute hospitals contributes to patient distress, opioid withdrawal and discharge against medical advice (DAMA). We aimed to improve access to opioid substitution therapy (OST) for hospital inpatients, using the iHOST (‘improving hospital opioid substitution therapy’) clinical guidelines, developed through a deliberative consensus process in partnership with clinical, academic and peer experts with professional body oversight. Methods: This pre–post quality improvement study evaluates implementation of the iHOST guideline at a tertiary hospital serving inner city London, UK between 2021 and 2023. Clinical records of all patients administered OST in the 12 months before and 11 months after the policy’s introduction were evaluated for measures of process (reducing urine drug screening, improving time-to-administration), balancing (avoiding emergency naloxone administration, avoiding increased mortality) and outcome (discharge against medical advice). Results: Among 259 patients pre-policy and 194 post-policy, the median time to first methadone dose fell from 18.1 hours to 14.8 hours and the proportion of patients waiting more than 24 hours reduced from 32% to 21% (OR 0.57, 95% CI 0.37 to 0.88). Urine drug screening was one-sixth as likely to be performed on admission. There was no change in the likelihood of discharge against medical advice, which occurred for 24% of admissions during both periods (p=0.96). Naloxone was required for only 2% of admissions (five pre-policy, four times post p=1.00), indicating no compromise of patient safety. Conclusions: Implementing the iHOST guideline successfully reduced unnecessary delays to methadone administration without increasing the risk of opioid toxicity. While high rates of DAMA, even after improving access to OST, point to an ongoing need for patient-centred engagement strategies, successful implementation of the iHOST guideline supports its wider use: it is now under evaluation in two additional hospitals, after which it will be optimised to assess its utility for nation-wide practice.
- 7 July 2026
- Published by BMJ in BMJ Open Quality
- Vol. 15 (3) , e004153
Open AccessImproving opioid substitution therapy in the acute hospital setting: implementation of a best practice guideline
Background: Delayed provision of opioid substitution therapy (OST) in acute hospitals contributes to patient distress, opioid withdrawal and discharge against medical advice (DAMA). We aimed to improve access to opioid substitution therapy (OST) for hospital inpatients, using the iHOST (‘improving hospital opioid substitution therapy’) clinical guidelines, developed through a deliberative consensus process in partnership with clinical, academic and peer experts with professional body oversight. Methods: This pre–post quality improvement study evaluates implementation of the iHOST guideline at a tertiary hospital serving inner city London, UK between 2021 and 2023. Clinical records of all patients administered OST in the 12 months before and 11 months after the policy’s introduction were evaluated for measures of process (reducing urine drug screening, improving time-to-administration), balancing (avoiding emergency naloxone administration, avoiding increased mortality) and outcome (discharge against medical advice). Results: Among 259 patients pre-policy and 194 post-policy, the median time to first methadone dose fell from 18.1 hours to 14.8 hours and the proportion of patients waiting more than 24 hours reduced from 32% to 21% (OR 0.57, 95% CI 0.37 to 0.88). Urine drug screening was one-sixth as likely to be performed on admission. There was no change in the likelihood of discharge against medical advice, which occurred for 24% of admissions during both periods (p=0.96). Naloxone was required for only 2% of admissions (five pre-policy, four times post p=1.00), indicating no compromise of patient safety. Conclusions: Implementing the iHOST guideline successfully reduced unnecessary delays to methadone administration without increasing the risk of opioid toxicity. While high rates of DAMA, even after improving access to OST, point to an ongoing need for patient-centred engagement strategies, successful implementation of the iHOST guideline supports its wider use: it is now under evaluation in two additional hospitals, after which it will be optimised to assess its utility for nation-wide practice.
- Open Access
- 9 May 2026
- Published by Springer Nature in Harm Reduction Journal
- Vol. 23 (1)
Innovation, respiration and drug paraphernalia policy: a mixed methods study of crack pipe practice and respiratory harm in England
Background: Provision of equipment for the purpose of stimulant inhalation is prohibited under UK law. Crack cocaine use is prevalent and rising in England, where the SIPP (safer inhalation pipe provision) study piloted and evaluated a crack equipment and workforce training intervention. We report mixed method findings from the baseline component of the study, prior to intervention implementation. The aim of this paper is to situate quantitative findings regarding respiratory risk through qualitative exploration of crack inhalation practice in a context of stimulant equipment prohibition. Methods: In this paper we report descriptive findings from baseline survey data ( n = 727) with a focus on thematic analysis of interview data ( n = 33). Participants were recruited through drug treatment services and peer networks in six geographical locations in England, with survey eligibility criteria including crack use (injecting or smoking) in the past 28 days. Findings: Of the 733 participants who completed the baseline questionnaire, 727 (99%) smoked crack in the past month and were included for further analysis. A minority reported crack injection (28%). Over half (55%) used crack daily in the past month. Many (60%) reported respiratory symptoms, with one third experiencing a respiratory-related hospitalisation. Qualitative data illustrate ingenuity of crack equipment practice, with participants fashioning pipes out of materials ranging from umbrella handles, through to tin cans and plastic inhaler cases. Ash and stainless-steel scourer were primarily used as suspension materials. Accounts of practice illustrate connections between materials used and respiratory harms, the latter exacerbated by poor living conditions and limited availability of supports. Conclusion: We evidence a high burden of respiratory harm among people who smoke crack in England. Stimulant inhalation equipment prohibition contributes to a constellation of respiratory risk, with use of unsafe materials and impoverished living environments exacerbating health harms among a highly marginalised population. There is a need to reorientate drug services to support safer crack inhalation practice and reduce respiratory risk. Legislative change can facilitate this process. Trial registration: ISRCTN12541454 https://doi.org/10.1186/ISRCTN12541454 .
- 9 May 2026
- Published by Springer Nature in Harm Reduction Journal
- Vol. 23 (1)
Open AccessInnovation, respiration and drug paraphernalia policy: a mixed methods study of crack pipe practice and respiratory harm in England
Background: Provision of equipment for the purpose of stimulant inhalation is prohibited under UK law. Crack cocaine use is prevalent and rising in England, where the SIPP (safer inhalation pipe provision) study piloted and evaluated a crack equipment and workforce training intervention. We report mixed method findings from the baseline component of the study, prior to intervention implementation. The aim of this paper is to situate quantitative findings regarding respiratory risk through qualitative exploration of crack inhalation practice in a context of stimulant equipment prohibition. Methods: In this paper we report descriptive findings from baseline survey data ( n = 727) with a focus on thematic analysis of interview data ( n = 33). Participants were recruited through drug treatment services and peer networks in six geographical locations in England, with survey eligibility criteria including crack use (injecting or smoking) in the past 28 days. Findings: Of the 733 participants who completed the baseline questionnaire, 727 (99%) smoked crack in the past month and were included for further analysis. A minority reported crack injection (28%). Over half (55%) used crack daily in the past month. Many (60%) reported respiratory symptoms, with one third experiencing a respiratory-related hospitalisation. Qualitative data illustrate ingenuity of crack equipment practice, with participants fashioning pipes out of materials ranging from umbrella handles, through to tin cans and plastic inhaler cases. Ash and stainless-steel scourer were primarily used as suspension materials. Accounts of practice illustrate connections between materials used and respiratory harms, the latter exacerbated by poor living conditions and limited availability of supports. Conclusion: We evidence a high burden of respiratory harm among people who smoke crack in England. Stimulant inhalation equipment prohibition contributes to a constellation of respiratory risk, with use of unsafe materials and impoverished living environments exacerbating health harms among a highly marginalised population. There is a need to reorientate drug services to support safer crack inhalation practice and reduce respiratory risk. Legislative change can facilitate this process. Trial registration: ISRCTN12541454 https://doi.org/10.1186/ISRCTN12541454 .
- Open Access
- 8 February 2026
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 64 (4) , 311-323
Is nitazene-related mortality underestimated? Findings from an in vivo and ex vivo rat study and pharmacoepidemiological analysis of coroner-reported deaths
Nitazenes are potent synthetic opioids. Following reports questioning their post-mortem stability, nitazene-related deaths may have been underestimated in the United Kingdom. We investigated this using a rat model and regional coronial data, and also present national pharmacoepidemiologic trends in nitazene-related deaths. In vivo/ex vivo study: Anaesthetised Wistar rats (n = 12) received intravenous nitazene (metonitazene, N-desethyl isotonitazene, or N-pyrrolidino etonitazene). Rats were euthanised 15 min post-administration if cardiorespiratory arrest had not already occurred (n = 8). Blood and urine were collected, with repeat blood samples taken following cadaver refrigeration (4 °C) for one week. All samples were immediately frozen (-80 °C). Upon defrosting, half were analysed immediately by liquid chromatography tandem mass spectroscopy with half stored at 4 °C for 1 month before analysis. Nitazene deaths were extracted from the National Programme on Substance Use Mortality in March 2025 along with all deaths from the Birmingham & Solihull coronial area (2019-2023). Descriptive analyses were conducted along with exponential smoothing models to compare observed and forecasted deaths in Birmingham & Solihull in 2023. In vivo/ex vivo study: A small fraction of the nitazene detected in the immediate post-mortem blood sample remained in the post-mortem day 7 blood sample that had been refrigerated for 1 month. In Birmingham and Solihull, non-nitazene drug deaths rose 33% in 2023 compared to 2019-2022 (predicted n = 107, actual n = 142). By March 2025, 285 deaths with nitazene detections were reported to the National Programme on Substance Use Mortality, with small clusters in 2021 (n = 23) and 2022 (n = 15) before markedly increasing in 2023 (n = 131). Twelve nitazenes were detected with the predominant nitazene shifting over time (2021: isotonitazene; 2022: N-pyrrolidino etonitazene; 2023: N-desethyl isotonitazene). Coroners deemed nitazenes causative in 90% of cases (n = 256/285). Nitazene-related deaths have increased in England, Wales, and Northern Ireland, and may have been underestimated due to post-mortem instability. Urgent public health action is required to reduce nitazene-related harms.
- 8 February 2026
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 64 (4) , 311-323
Open AccessIs nitazene-related mortality underestimated? Findings from an in vivo and ex vivo rat study and pharmacoepidemiological analysis of coroner-reported deaths
Nitazenes are potent synthetic opioids. Following reports questioning their post-mortem stability, nitazene-related deaths may have been underestimated in the United Kingdom. We investigated this using a rat model and regional coronial data, and also present national pharmacoepidemiologic trends in nitazene-related deaths. In vivo/ex vivo study: Anaesthetised Wistar rats (n = 12) received intravenous nitazene (metonitazene, N-desethyl isotonitazene, or N-pyrrolidino etonitazene). Rats were euthanised 15 min post-administration if cardiorespiratory arrest had not already occurred (n = 8). Blood and urine were collected, with repeat blood samples taken following cadaver refrigeration (4 °C) for one week. All samples were immediately frozen (-80 °C). Upon defrosting, half were analysed immediately by liquid chromatography tandem mass spectroscopy with half stored at 4 °C for 1 month before analysis. Nitazene deaths were extracted from the National Programme on Substance Use Mortality in March 2025 along with all deaths from the Birmingham & Solihull coronial area (2019-2023). Descriptive analyses were conducted along with exponential smoothing models to compare observed and forecasted deaths in Birmingham & Solihull in 2023. In vivo/ex vivo study: A small fraction of the nitazene detected in the immediate post-mortem blood sample remained in the post-mortem day 7 blood sample that had been refrigerated for 1 month. In Birmingham and Solihull, non-nitazene drug deaths rose 33% in 2023 compared to 2019-2022 (predicted n = 107, actual n = 142). By March 2025, 285 deaths with nitazene detections were reported to the National Programme on Substance Use Mortality, with small clusters in 2021 (n = 23) and 2022 (n = 15) before markedly increasing in 2023 (n = 131). Twelve nitazenes were detected with the predominant nitazene shifting over time (2021: isotonitazene; 2022: N-pyrrolidino etonitazene; 2023: N-desethyl isotonitazene). Coroners deemed nitazenes causative in 90% of cases (n = 256/285). Nitazene-related deaths have increased in England, Wales, and Northern Ireland, and may have been underestimated due to post-mortem instability. Urgent public health action is required to reduce nitazene-related harms.
- Open Access
- 28 January 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 149, 105165
Pipes as an engagement tool: qualitative findings from a crack equipment and harm reduction training intervention in England
- 28 January 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 149, 105165
Open AccessPipes as an engagement tool: qualitative findings from a crack equipment and harm reduction training intervention in England
- Open Access
- 11 July 2025
- Published by Wiley in British Journal of Health Psychology
- Vol. 30 (3) , e70005
Post‐treatment life‐trajectories among people who inject drugs who completed hepatitis C treatment with direct acting antivirals: A thematic analysis
Background: Hepatitis C Virus is a global health burden, particularly affecting people who inject drugs. Direct‐acting antiviral treatment can cure almost all people infected with hepatitis C. However, the longer‐term impacts on within people's life trajectories are unknown, although some suggest it may lead to fundamental behavioural changes. Design: A cross‐sectional exploratory retrospective qualitative design. Methods: We interviewed 30 people who inject(ed) drugs and who had previously been treated with direct‐acting antivirals on average 18 months before the interview (range: 12–24 months). Most were male, aged 36–55 years, and had been treated in urban community‐based needle and syringe programmes in Scotland. All interviews were semi‐structured, conducted over the phone by either peer or academic researchers, and analysed thematically. Results: We present three discernible post‐treatment life‐trajectories. Firstly, ‘ A cure that was like totally new life’ involved identity transformation, often associated with controlled or zero drug use, and improved physical and mental health. Secondly, ‘ There isn't much afterwards ’ comprised poor quality of life and social isolation, often due to participants' disengagement from former drug use and support networks. Thirdly, ‘ I'm getting tested every year now’ detailed a few life changes but normalized hepatitis C testing and treatment. Conclusion: Our thematic analysis reinforces the positive impacts on mental well‐being, physical health and self‐transformation of direct‐acting antiviral treatment in the short‐ and long‐term. However, there is an urgent need for psychosocial interventions to maintain health behaviour changes and self‐management, and social support for individuals post hepatitis C treatment.
- 11 July 2025
- Published by Wiley in British Journal of Health Psychology
- Vol. 30 (3) , e70005
Open AccessPost‐treatment life‐trajectories among people who inject drugs who completed hepatitis C treatment with direct acting antivirals: A thematic analysis
Background: Hepatitis C Virus is a global health burden, particularly affecting people who inject drugs. Direct‐acting antiviral treatment can cure almost all people infected with hepatitis C. However, the longer‐term impacts on within people's life trajectories are unknown, although some suggest it may lead to fundamental behavioural changes. Design: A cross‐sectional exploratory retrospective qualitative design. Methods: We interviewed 30 people who inject(ed) drugs and who had previously been treated with direct‐acting antivirals on average 18 months before the interview (range: 12–24 months). Most were male, aged 36–55 years, and had been treated in urban community‐based needle and syringe programmes in Scotland. All interviews were semi‐structured, conducted over the phone by either peer or academic researchers, and analysed thematically. Results: We present three discernible post‐treatment life‐trajectories. Firstly, ‘ A cure that was like totally new life’ involved identity transformation, often associated with controlled or zero drug use, and improved physical and mental health. Secondly, ‘ There isn't much afterwards ’ comprised poor quality of life and social isolation, often due to participants' disengagement from former drug use and support networks. Thirdly, ‘ I'm getting tested every year now’ detailed a few life changes but normalized hepatitis C testing and treatment. Conclusion: Our thematic analysis reinforces the positive impacts on mental well‐being, physical health and self‐transformation of direct‐acting antiviral treatment in the short‐ and long‐term. However, there is an urgent need for psychosocial interventions to maintain health behaviour changes and self‐management, and social support for individuals post hepatitis C treatment.
- Open Access
- 30 May 2025
- Published by Public Library of Science (PLoS) in PLOS Mental Health
- Vol. 2 (5) , e0000322
Interventions to improve access to opioid agonist therapy in acute hospitals: A scoping review
Many people who use illicit opioids have negative experiences when admitted to hospital, which is partly due to poor availability of opioid agonist therapy (OAT). We conducted a scoping review of interventions to increase access OAT to for hospital patients, with searches of MEDLINE, EMBASE, PsychINFO, and CINAHL for evaluations published before 29 July 2024. We followed a registered protocol (identifier: CRD42022313237). We included interventions in acute inpatient or emergency department settings, and extracted intervention characteristics, location, evaluation design and quality, and evidence for effectiveness. We included 57 studies; 50 from the United States, six from Canada, and one from the UK. Fifty-one were published in 2015 or later. We identified three intervention classes: (a) pathways to initiate OAT in emergency departments, entailing screening patients or training staff to identify withdrawal, initiating buprenorphine, and supported referrals (26 studies); (b) multidisciplinary ‘addiction consult teams’, which provide substance-related care across hospital departments, advise primary medical teams on issues such as pain relief and withdrawal management, and support patients with discharge and onward care (18 studies); and (c) Interventions that build capacity of general clinical teams to provide OAT to inpatients, including protocols to identify patients who need OAT, multidisciplinary patient review, and training/clinical education (13 studies). Most interventions included multiple components, and the most common were clinical education and measures to improve continuity of OAT after discharge, such as bridge prescriptions and supported referrals to community prescribers. Almost all studies concluded that interventions were effective, however evaluation methods were generally weak and most used before/after or case series designs. Efforts to improve OAT in acute hospitals emerged recently in North America and focus on addiction consult teams and initiation of buprenorphine in emergency departments. Although formal evaluation is weak, these models may represent starting points for national policy and larger research programmes.
- 30 May 2025
- Published by Public Library of Science (PLoS) in PLOS Mental Health
- Vol. 2 (5) , e0000322
Open AccessInterventions to improve access to opioid agonist therapy in acute hospitals: A scoping review
Many people who use illicit opioids have negative experiences when admitted to hospital, which is partly due to poor availability of opioid agonist therapy (OAT). We conducted a scoping review of interventions to increase access OAT to for hospital patients, with searches of MEDLINE, EMBASE, PsychINFO, and CINAHL for evaluations published before 29 July 2024. We followed a registered protocol (identifier: CRD42022313237). We included interventions in acute inpatient or emergency department settings, and extracted intervention characteristics, location, evaluation design and quality, and evidence for effectiveness. We included 57 studies; 50 from the United States, six from Canada, and one from the UK. Fifty-one were published in 2015 or later. We identified three intervention classes: (a) pathways to initiate OAT in emergency departments, entailing screening patients or training staff to identify withdrawal, initiating buprenorphine, and supported referrals (26 studies); (b) multidisciplinary ‘addiction consult teams’, which provide substance-related care across hospital departments, advise primary medical teams on issues such as pain relief and withdrawal management, and support patients with discharge and onward care (18 studies); and (c) Interventions that build capacity of general clinical teams to provide OAT to inpatients, including protocols to identify patients who need OAT, multidisciplinary patient review, and training/clinical education (13 studies). Most interventions included multiple components, and the most common were clinical education and measures to improve continuity of OAT after discharge, such as bridge prescriptions and supported referrals to community prescribers. Almost all studies concluded that interventions were effective, however evaluation methods were generally weak and most used before/after or case series designs. Efforts to improve OAT in acute hospitals emerged recently in North America and focus on addiction consult teams and initiation of buprenorphine in emergency departments. Although formal evaluation is weak, these models may represent starting points for national policy and larger research programmes.
- Open Access
- 18 November 2024
- Published by Springer Nature in Harm Reduction Journal
- Vol. 21 (1) , 1-11
Improving hospital care for people who use drugs: deliberative process development of a clinical guideline for opioid withdrawal management
Background: Management of opioid withdrawal in hospital settings is crucial to improve treatment completion and health outcomes among patients who use opioids, such as heroin. Evidence-based clinical guidelines can support responsive provision of opioid substitution therapy (OST). In England there is no standardised application of guidance for substance dependence management across National Health Service (NHS) Hospitals. A recent review of NHS hospital policies identified varying approaches to managing opioid withdrawal and procedural barriers to timely medication. Objective: To develop a clinical guideline for opioid withdrawal management in acute NHS hospital trusts to be tested and evaluated as part of the iHOST (Improving Hospital Opioid Substitution Therapy) research intervention. Methods: We undertook a deliberative guideline development process. The University London College Hospital (UCLH) substance dependence guideline was used as a template, with key points of revision informed by evidence review, consultations with hospital staff and people with opioid dependence. A multidisciplinary working group deliberated evidence statements to develop recommendations. These were reviewed by an oversight committee comprising representatives from key stakeholder organisations. The team authored the guideline with iterative review by the oversight committee, key stakeholders and UCLH clinical governance committees. Results: Deliberation focused on three key domains: (1) identifying opioid dependence and promptly continuing existing OST prescriptions; (2) initiating or re-titrating OST; (3) ensuring safety and continuity of care at discharge. Changes to the UCLH guideline included removal of mandatory urine drug testing prior to OST; increasing initial methadone titration dose; and provision for a higher day-one titration dose when specific safety criteria are met. A new titration schedule for sublingual buprenorphine was incorporated. Discharge planning to ensure continuity of community care and reduce risk of opioid overdose was emphasised, with allowance for bridging prescriptions of OST and naloxone provision on hospital discharge. Conclusion: The iHOST clinical guideline aims to remove procedural barriers to opioid withdrawal management for hospital inpatients. It is intended to be implemented by other NHS hospitals, which could improve access to OST and reduce discrepancies in treatment access and completion. Study registration: ISRCTN47320412 https://doi.org/10.1186/ISRCTN47320412.
- 18 November 2024
- Published by Springer Nature in Harm Reduction Journal
- Vol. 21 (1) , 1-11
Open AccessImproving hospital care for people who use drugs: deliberative process development of a clinical guideline for opioid withdrawal management
Background: Management of opioid withdrawal in hospital settings is crucial to improve treatment completion and health outcomes among patients who use opioids, such as heroin. Evidence-based clinical guidelines can support responsive provision of opioid substitution therapy (OST). In England there is no standardised application of guidance for substance dependence management across National Health Service (NHS) Hospitals. A recent review of NHS hospital policies identified varying approaches to managing opioid withdrawal and procedural barriers to timely medication. Objective: To develop a clinical guideline for opioid withdrawal management in acute NHS hospital trusts to be tested and evaluated as part of the iHOST (Improving Hospital Opioid Substitution Therapy) research intervention. Methods: We undertook a deliberative guideline development process. The University London College Hospital (UCLH) substance dependence guideline was used as a template, with key points of revision informed by evidence review, consultations with hospital staff and people with opioid dependence. A multidisciplinary working group deliberated evidence statements to develop recommendations. These were reviewed by an oversight committee comprising representatives from key stakeholder organisations. The team authored the guideline with iterative review by the oversight committee, key stakeholders and UCLH clinical governance committees. Results: Deliberation focused on three key domains: (1) identifying opioid dependence and promptly continuing existing OST prescriptions; (2) initiating or re-titrating OST; (3) ensuring safety and continuity of care at discharge. Changes to the UCLH guideline included removal of mandatory urine drug testing prior to OST; increasing initial methadone titration dose; and provision for a higher day-one titration dose when specific safety criteria are met. A new titration schedule for sublingual buprenorphine was incorporated. Discharge planning to ensure continuity of community care and reduce risk of opioid overdose was emphasised, with allowance for bridging prescriptions of OST and naloxone provision on hospital discharge. Conclusion: The iHOST clinical guideline aims to remove procedural barriers to opioid withdrawal management for hospital inpatients. It is intended to be implemented by other NHS hospitals, which could improve access to OST and reduce discrepancies in treatment access and completion. Study registration: ISRCTN47320412 https://doi.org/10.1186/ISRCTN47320412.
- Open Access
- 6 November 2024
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 4, 10
Improving hospital-based opioid substitution therapy (iHOST): protocol for a mixed-methods evaluation
Background Opioid substitution therapy (also known as ‘opioid agonist therapy’ or ‘medication treatment of opioid use disorder’) is associated with improved health and social outcomes for people who use heroin and other illicit opioids. It is typically managed in the community and is not always continued when people are admitted to hospital. This causes opioid withdrawal, patient-directed discharge, and increased costs. We are establishing a project called iHOST (improving hospital opioid substitution therapy) to address these problems. This is an applied health research project in which we will develop and evaluate an intervention that aims to improve opioid substitution therapy in three acute hospitals in England. The intervention was developed in collaboration with stakeholders including people who use opioids, hospital staff, and other professionals who work with this group. It includes five components: (1) a card that patients can use to help hospital clinicians confirm their opioid substitution therapy, (2) a helpline for patients and staff, (3) an online training module for staff, (4) a clinical guideline for managing opioid withdrawal in hospital, and (5) ‘champion’ roles at each hospital. Methods We will do a mixed-methods study including a quasi-experimental quantitative study and a qualitative process evaluation. The primary outcomes for the quantitative study are patient-directed discharge and emergency readmission within 28 days. We will do a difference-in-difference analysis comparing changes in these outcomes for patients at iHOST sites with changes for patients at control hospitals. The process evaluation will use in-depth interviews, focus groups, and site observations with people who use opioids and staff. We will assess acceptability of the intervention, barriers and facilitators to implementation, and contextual factors impacting outcomes. Impact We anticipate that iHOST will improve care for hospital patients who use illicit opioids and/or are receiving community-based opioid substitution therapy. Depending on the results, we will promote the intervention at hospitals across the UK. Dissemination, including through publication, will inform hospital-based services for people who use drugs both in the UK and other countries.
- 6 November 2024
- Published by National Institute for Health and Care Research in NIHR Open Research
- Vol. 4, 10
Open AccessImproving hospital-based opioid substitution therapy (iHOST): protocol for a mixed-methods evaluation
Background Opioid substitution therapy (also known as ‘opioid agonist therapy’ or ‘medication treatment of opioid use disorder’) is associated with improved health and social outcomes for people who use heroin and other illicit opioids. It is typically managed in the community and is not always continued when people are admitted to hospital. This causes opioid withdrawal, patient-directed discharge, and increased costs. We are establishing a project called iHOST (improving hospital opioid substitution therapy) to address these problems. This is an applied health research project in which we will develop and evaluate an intervention that aims to improve opioid substitution therapy in three acute hospitals in England. The intervention was developed in collaboration with stakeholders including people who use opioids, hospital staff, and other professionals who work with this group. It includes five components: (1) a card that patients can use to help hospital clinicians confirm their opioid substitution therapy, (2) a helpline for patients and staff, (3) an online training module for staff, (4) a clinical guideline for managing opioid withdrawal in hospital, and (5) ‘champion’ roles at each hospital. Methods We will do a mixed-methods study including a quasi-experimental quantitative study and a qualitative process evaluation. The primary outcomes for the quantitative study are patient-directed discharge and emergency readmission within 28 days. We will do a difference-in-difference analysis comparing changes in these outcomes for patients at iHOST sites with changes for patients at control hospitals. The process evaluation will use in-depth interviews, focus groups, and site observations with people who use opioids and staff. We will assess acceptability of the intervention, barriers and facilitators to implementation, and contextual factors impacting outcomes. Impact We anticipate that iHOST will improve care for hospital patients who use illicit opioids and/or are receiving community-based opioid substitution therapy. Depending on the results, we will promote the intervention at hospitals across the UK. Dissemination, including through publication, will inform hospital-based services for people who use drugs both in the UK and other countries.
- Open Access
Social determinants of injection drug use-associated bacterial infections and treatment outcomes: systematic review and meta-analysis
Background Individual injecting practices (e.g., intramuscular injecting, lack of skin cleaning) are known risk factors for injection drug use-associated bacterial and fungal infections; however, social contexts shape individual behaviours and health outcomes. We sought to synthesize studies assessing potential social determinants of injecting-related infections and treatment outcomes. Methods We searched five databases for studies published between 1 January 2000 and 18 February 18 2021 (PROSPERO CRD42021231411). We included studies of association (aetiology), assessing social determinants, substance use, and health services exposures influencing development of injecting-related infections and treatment outcomes. We pooled effect estimates via random effects meta-analyses. Results We screened 4,841 abstracts and included 107 studies. Several factors were associated with incident or prevalent injecting-related infections: woman/female gender/sex (adjusted odds ratio [aOR] 1.57, 95% confidence interval [CI] 1.36-1.83; n=20 studies), homelessness (aOR 1.29, 95%CI 1.16-1.45; n=13 studies), cocaine use (aOR 1.31, 95%CI 1.02–1.69; n=10 studies), amphetamine use (aOR 1.74, 95%CI 1.39-2.23; n=2 studies), public injecting (aOR 1.40, 95%CI 1.05–1.88; n=2 studies), requiring injecting assistance (aOR 1.78, 95%CI 1.40–2.27; n=8 studies), and use of opioid agonist treatment (aOR 0.92, 95%CI 0.89–0.95; n=9 studies). Studies assessing outcomes during treatment (e.g., premature hospital discharge) or afterward (e.g., rehospitalization; all-cause mortality) typically had smaller sample sizes and imprecise effect estimates. Conclusions Injecting-related infections and treatment outcomes may be shaped by multiple social contextual factors. Approaches to prevention and treatment should look beyond individual injecting practices towards addressing the social and material conditions within which people live, acquire and consume drugs, and access health care.
Open AccessSocial determinants of injection drug use-associated bacterial infections and treatment outcomes: systematic review and meta-analysis
Background Individual injecting practices (e.g., intramuscular injecting, lack of skin cleaning) are known risk factors for injection drug use-associated bacterial and fungal infections; however, social contexts shape individual behaviours and health outcomes. We sought to synthesize studies assessing potential social determinants of injecting-related infections and treatment outcomes. Methods We searched five databases for studies published between 1 January 2000 and 18 February 18 2021 (PROSPERO CRD42021231411). We included studies of association (aetiology), assessing social determinants, substance use, and health services exposures influencing development of injecting-related infections and treatment outcomes. We pooled effect estimates via random effects meta-analyses. Results We screened 4,841 abstracts and included 107 studies. Several factors were associated with incident or prevalent injecting-related infections: woman/female gender/sex (adjusted odds ratio [aOR] 1.57, 95% confidence interval [CI] 1.36-1.83; n=20 studies), homelessness (aOR 1.29, 95%CI 1.16-1.45; n=13 studies), cocaine use (aOR 1.31, 95%CI 1.02–1.69; n=10 studies), amphetamine use (aOR 1.74, 95%CI 1.39-2.23; n=2 studies), public injecting (aOR 1.40, 95%CI 1.05–1.88; n=2 studies), requiring injecting assistance (aOR 1.78, 95%CI 1.40–2.27; n=8 studies), and use of opioid agonist treatment (aOR 0.92, 95%CI 0.89–0.95; n=9 studies). Studies assessing outcomes during treatment (e.g., premature hospital discharge) or afterward (e.g., rehospitalization; all-cause mortality) typically had smaller sample sizes and imprecise effect estimates. Conclusions Injecting-related infections and treatment outcomes may be shaped by multiple social contextual factors. Approaches to prevention and treatment should look beyond individual injecting practices towards addressing the social and material conditions within which people live, acquire and consume drugs, and access health care.